

## INVESTMENT TEASER – SERIES A



### Profile

**CasInvent Pharma** is Czech Republic leading drug discovery company developing a new class of proprietary small molecule compounds with in vivo activities in various cancers (liquid & solid). The company has been seed-funded by i&i Prague with further investment provided by KHAN-I, i&i BIO, Holecek Family Foundation, Garage Angels, JIC Ventures, BIOINVESTIMED and Dynumerics. We are currently advancing the lead compound through late-stage preclinical development starting IND filing activities.

### Our Solution

The **small-molecule** inhibitors developed by CasInvent Pharma are the **first and best in class compounds designed to target with high potency all three individual isoforms** of serine-threonine kinases from the Casein kinase 1 (CK1) family. The lead compound, chosen out of a series of > 500 molecules, exhibits exceptional efficacy in vivo in AML and overcomes resistance induced by SoC treatment.

Simultaneous inhibition of all CK1  $\alpha/\delta/\epsilon$  bypasses cancer adaptation mechanisms to targeted therapies. Thus, the development of CK1 inhibitors is dedicated but not restricted to the following indications:

- Venetoclax-resistant Acute Myeloid Leukemia (AML)
- BRAF inhibitor resistant melanoma patients
- Gemcitabine-resistant Pancreatic Cancer (PDAC)

### IP

CasInvent Pharma holds exclusive licensing rights since 2020 to patented technology ([WO2019185631](#)), providing robust IP protection to support the company's clinical and commercial development.

### Competition

CK1 inhibitors are being explored by pharma and biotech companies in oncology and CNS disorders (e.g., ALS, autism, and circadian rhythm). However, most current Phase II programs focus only on CK1 $\alpha$ , often using targeted degraders. **Our compounds are unique in inhibiting all three CK1 isoforms ( $\alpha/\delta/\epsilon$ ), which is synthetically challenging and market differentiating.** This pan-isoform approach is expected to deliver greater efficacy and a broader therapeutic window compared to CK1 $\alpha$ -only degraders. Given recent high-profile publications and increasing biotech interest in CK1, pan isoform CK1 inhibitors like ours **hold significant blockbuster potential across oncology and CNS indications.**

Company Summary	
Company	<b>CasInvent Pharma, a.s.</b>
Industry	<b>Pharmaceuticals - oncology</b>
Founded	<b>2020</b>
Management	<b>CEO &amp; CSO - Alexander Scheer</b> <b>CFO &amp; COO - Vojtech Helikar</b> <b>Non-executive Director BD - Natalie Novac</b> <b>Alliance Manager - Tomas Prat</b> <b>Head of Biology - Tomasz Radaszkiewicz</b> <b>Head of Chemistry - Kamil Paruch</b>
IP Status	<b>Patent granted, exclusively licenced</b>
Indications	<b>AML (Acute Myeloid Leukemia )</b> <b>Melanoma, PDAC, Prostate cancer etc</b>
Financing Sought	<b>€ 10-12 M</b>
Use of Funds	<b>Reaching clinical proof-of-concept</b> <b>New lead compounds for new indications</b>
Planned Exit	<b>2029</b>

### Current Status of Development

**CasInvent Pharma** is currently in the preclinical stages of development. The IND filing is planned for 2026 after the completion of the advanced toxicology studies. Entry into the clinical phase Ia/b is planned for 2026/2027, with the exit of CasInvent Pharma envisaged for 2029.

### Value Proposition

**CasInvent Pharma seeks € 10-12 M to reach the clinical stage of development in 2027 and to obtain clinical proof-of-concept in 2028.**

Please contact us at [scheer@casinvent.com](mailto:scheer@casinvent.com) for more details about our science and fundraising